TP53 and cervical cancer: With this in mind, and considering the strong Chk1 activation in response to 1, HeLa cervical cancer cells, which are p53-mutant44, were exposed to a combination of 1 plus the Chk1 inhibitor CHIR-12445 and the impact of co-treatment upon cell viability determined.